

AD _____

Award Number: DAMD17-98-1-8584

TITLE: Regulation of Androgen Responses in Prostate Cancer by
BAG-1

PRINCIPAL INVESTIGATOR: John C. Reed, M.D., Ph.D.

CONTRACTING ORGANIZATION: The Burnham Institute
La Jolla, California 92037

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)

September 1999

3. REPORT TYPE AND DATES COVERED

Annual (1 Sep 98 - 31 Aug 99)

4. TITLE AND SUBTITLE

Regulation of Androgen Responses in Prostate Cancer by BAG1

5. FUNDING NUMBERS

DAMD17-98-1-8584

6. AUTHOR(S)

John C. Reed, M.D., Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

The Burnham Institute

La Jolla, California 92037

**8. PERFORMING ORGANIZATION
REPORT NUMBER****E-MAIL:**

Jreed@burnham-inst.org

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

**10. SPONSORING / MONITORING
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE**13. ABSTRACT (Maximum 200 Words)**

Androgen ablation therapy and anti-androgenic drugs represent the principal treatments for metastatic prostate cancer. However, nearly all tumors eventually relapse as hormone-refractory disease. A need therefore exists for better understanding of the mechanisms that allow prostate cancer cells to grow in an androgen - independent manner. This study focuses on BAG-1, a protein that is expressed in prostate cancers and which binds to androgen receptors, increasing their sensitivity to androgenic hormones. BAG-1 is a novel regulator of Hsp70 family molecular chaperones that was originally cloned in our laboratory. The activity of many steroid hormone receptors is known to be regulated by Hsp70 and Hsp90 family proteins. Recently, we have discovered that a previously unrecognized isoform of BAG-1, termed BAG-1L, can form complexes with androgen receptors (AR) and potentiate the actions of AR in prostate cancers, markedly lowering the concentrations of dihydrotestosterone needed for AR-mediated transactivation. In contrast, the shorter BAG-1 protein forms complexes with RAR family retinoid receptors, preventing retinoid-induced transactivation of target genes, abrogating cell growth suppression, and blocking apoptosis. Since BAG-1 and BAG-1L are commonly expressed in prostate cancers, we hypothesize that these proteins contribute to mechanisms of tumor resistance to anti-androgen and retinoid-based therapy. In this proposal, we describe experiments designed to further explore the biological roles and molecular mechanisms by which BAG-1 and BAG-1L regulate responses of prostate cancers to steroid hormones that control the proliferation, differentiation and survival of these malignancies.

14. SUBJECT TERMS

Prostate Cancer

15. NUMBER OF PAGES

11

16. PRICE CODE**17. SECURITY CLASSIFICATION
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION
OF ABSTRACT**

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

20010302 062

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

N/A Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


√ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

√ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

√ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

√ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

Date

Annual Report
DAMD17-98-1-8584

John C. Reed, MD, Ph.D.

**Regulation of Androgen Responses in Prostate
Cancer by BAG-1**

TABLE OF CONTENTS	PAGE
INTRODUCTION	3
BODY	5
CONCLUSION	7

INTRODUCTION

Prostate cancer is an androgen-driven disease. In the absence of testosterone or related androgens which can serve as ligands for the androgen receptor, the secretory epithelial cells of the prostate undergo rapid programmed cell death (1). Current treatment for metastatic adenocarcinoma of the prostate is predicated on the cell death inducing effects of anti-androgens and hormone ablative measures which reduce endogenous production of androgens. However, nearly all hormone-dependent prostate cancers eventually relapse as fatal hormone-independent disease (2).

Multiple, still largely unidentified mechanisms may account for the complete independence or reduced dependence of prostate cancers on androgens (reviewed in (3-5). AR gene deletion and sequestration of AR in the cytoplasm have been described in some hormone-independent tumors, implying that genetic alterations associated with tumor progression can abrogate the necessity for AR in some cases. However, many tumors may rely on other strategies which allow cancer cells to grow in low concentrations of androgens, including AR gene amplification or over-expression (6, 7) and AR mutations which permit trans-activation of target genes with little or no requirement for steroid hormones (4, 8). Since most hormone-insensitive prostate cancers still retain a wild-type AR, presumably alterations in the factors that control the levels of AR and its function play a major role in resistance to anti-androgen and hormone ablative therapies. Thus, a need exists to understand more about the molecular mechanisms that govern the activity of ARs.

Upon binding steroid ligands, the AR undergoes a conformational change, translocates to the nucleus and binds to specific DNA sequences located near or in promoter regions of target genes. After binding DNA, the receptor interacts with components of the basal transcription machinery and sometimes sequence-specific transcription factors, resulting in positive or negative effects on gene transcription (9, 10). A number of proteins have been identified which associate with hormone-receptor complexes, including several heat shock family proteins and various types of transcription co-activators (reviewed in (11, 12). However, many details remain unclear as to the molecular mechanisms by which these proteins modulate the activities of steroid hormone receptors and even less is known about whether alterations in their expression or function might contribute to the deregulation of steroid hormone responses in prostate cancer.

In this proposal, we describe experiments designed to explore the biological significance and molecular mechanisms by which AR is regulated by BAG-1 family proteins. BAG-1 is a novel Hsp70-family binding protein cloned in our laboratory. We have discovered that an isoform of this protein, BAG-1L, forms complexes with AR and potentiates the activity of this steroid hormone receptor, allowing it to transactivate target genes with 100-1,000 x lower concentrations of dihydrotestosterone. We have also determined that BAG-1 and BAG-1L are expressed in most prostate cancers. Our goals now are to define the overall significance of BAG-1 family proteins on AR responses in prostate cancers and to delineate the mechanisms by which these Hsp70-binding proteins

control the function of AR and other steroid hormone receptors of relevance to prostate cancer cell growth, differentiation, and survival. These studies may reveal new strategies for improving androgen ablation therapy and attacking hormone-refractory metastatic prostate cancer.

BODY

OBJECTIVES

The original funded objectives of the project were to:

1. Determine the expression and location of BAG1 and BAG1L in primary and metastatic prostate cancer.
2. Study consequences of ablation of BAG1 and BAG1L expression in prostate cancer cell lines.
3. Examine in vivo effects of BAG1 and BAG1L on the androgen-dependence of the normal prostate gland.

PROGRESS

Objective #1. Determine the expression and location of BAG1 and BAG1L in primary and metastatic prostate cancer.

This aim has been partially accomplished. We generated monoclonal antibodies which recognize the BAG1 and the BAG1L proteins. We determined that BAG1 is cytosolic while BAG1L is nuclear. Using these monoclonal antibodies, we have used immunohistochemical methods and archival paraffin-embedded prostate cancer specimens to evaluate the expression of the nuclear (BAG1L) and cytosolic (BAG1) proteins in over 700 cases of prostate cancer. Comparisons were made with BAG1 immunostaining results in normal prostate and benign prostatic hypertrophy. Tissue microarray technology was exploited for much of this analysis, permitting us to analyze large numbers of tumor specimens.

BAG1 immunostaining was generally present in $\leq 30\%$ of normal prostate epithelial cells, with 51/54 normal specimens having $\leq 30\%$ BAG1 immunopositive epithelial cells. By comparison, most (91%) prostate cancers contained elevated percentages of BAG1 immunopositive cells, with 657 of 722 specimens (91%) having elevated percentages ($\geq 40\%$) of BAG-positive tumor cells. No correlations of BAG1 immunostaining data with Gleason grade or clinical stage. The percentages of BAG1 immunopositive cells were also not significantly different when comparing primary However, in men treated with radical prostatectomy ($n = 160$), log-rank analysis demonstrated an association between BAG1 immunostaining data and recurrence-free survival ($p = 0.009$), with higher percentages of BAG1 immunopositive cells associated with longer recurrence-free survival (median survival 4.6 versus 2.4 years). Further analysis of these data is underway, as we seek additional correlations of BAG1 immunostaining data with clinical endpoints.

From these observations, two conclusions can be reached. First, tumor-specific increases in BAG1 levels commonly occur in prostate cancers. Second,

compared to tumors that do not over-express BAG1, the expression of BAG1 may be associated with longer survival. However, since our antibodies do not discriminate between BAG1 and BAG1L, these results must be interpreted with caution. Efforts are underway to generate antibodies that react uniquely with the longer BAG1L protein, which is the isoform of the protein which has been shown to associated with AR and other nuclear hormone receptors.

Objective #2. Study consequences of ablation of BAG1 and BAG1L expression in prostate cancer cell lines.

To interfere with BAG1 and BAG1L function in prostate cancers, we have expressed mutants of BAG1 or BAG1L which lack the C-terminal domain required for Hsc70-binding, so-called ΔC mutants. Our initial efforts have focused on assessing the impact of these trans-dominant inhibitory mutants of BAG1 and BAG1L on function of the Androgen Receptor (AR). These studies revealed that BAG1L(ΔC) suppresses the function of the AR, preventing it from transactivating reporter genes in transient transfection reporter gene assays.

An initial description of this work has been published by our group, but additional work in which we have extended the analysis to other cell lines has confirmed and solidified these impressions (13). An example of an experiment is presented in Figure 1, where various concentrations of a plasmid encoding BAG1L(ΔC) were compared with another plasmid producing a BAG1L mutant missing its N-terminal 50 aminoacids, BAG1L(ΔN). The BAG1L(ΔC) protein interfered with AR-induced activation of a reporter gene plasmids, whereas the BAG1L(ΔN) protein did not.




Figure 1. BAG1L(Δ C) functions as a trans-dominant inhibitor which interferes with AR function. COS-7 cells were transfected with 0.04 μ g of pSG5-AR, 0.5 μ g of pLCL, 0.06 μ g of pCMV- β Gal, 0.03 μ g of pcDNA3-Bag1L and increasing amount of pcDNA3-Bag1L Δ 1-50 or pcDNA3-Bag1L Δ C. Total DNA was maintained at 1.4 μ g by the addition of empty plasmid. 30 hrs after transfection, cells were stimulated with 1nM R1881. Cell extracts were prepared and assayed for CAT and β -galactosidase activity at 40 hrs after transfection. Data are expressed as in Figure 1 (mean \pm S.D., n=2). We are now attempting to generate stable transfectants in prostate cancer cell lines so that we may complete this Objective.

Objective #3. Examine in vivo effects of BAG1 and BAG1L on the androgen-dependence of the normal prostate gland.

Efforts to generate transgenic mice expressing BAG1 or BAG1L under the control of a probasin promoter are underway. Constructs have been prepared and are undergoing testing by transfection in prostate cancer cell lines in vitro before progressing to transgenic mouse production.

PUBLICATIONS

No papers resulted from the work performed during the past funding period, but a manuscript is in preparation which describes the immunohistochemical analysis of BAG1 expression in prostate cancers (Objective #1) and another paper will soon be prepared resulting from our studies of trans-dominant inhibitory mutants of BAG1L (Objective #2).

CONCLUSION

Understanding the molecular basis for progression of prostate cancers to hormone-refractory disease is critical for designing new therapeutic strategies for the treatment of advanced prostate cancer. We have discovered a protein, BAG1L, that binds the androgen receptor (AR) and enhances its resistance to anti-androgenic agents. Our findings accomplished with funding from this grant indicate that BAG1 expression is abnormally elevated in the vast majority of prostate cancers. Future studies of the impact of BAG1 overexpression and BAG1 inhibition in the prostate glands of transgenic mice will reveal the overall significance of BAG1 for regulation of androgen-responses in normal and malignant prostate tissue, and will help contribute to new strategies for overcoming hormone-resistant prostate cancer.

REFERENCES

1. Kyprianou, N. and Isaacs, J. T. Activation of programmed cell death in the rat ventral prostate after castration, *Endocrinology*. 122: 552-562, 1988.
2. Crawford, E. D., Eisenberger, M. A., McLeod, D. C., Spaulding, J., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A control randomized trial of Leuprolide with and without flutamide in prostatic cancer, *N. Engl. J. Med.* 321: 419-424, 1989.
3. Marcelli, M., Tilley, W. D., Zoppi, S., Griffin, J. E., Wilson, J. D., and McPhaul, M. J. Molecular basis of androgen resistance, *J. Endocrinol. Invest.* 15: 149-159, 1992.
4. McPhaul, M. J., Marcelli, M., Zoppi, S., Griffin, J. E., and Wilson, J. D. Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance, *J. Clin. Endocrinol. Metab.* 76: 17-23, 1993.
5. Coetzee, G. A. and Ross, R. K. Prostate cancer and the androgen receptor, *J. Natl. Cancer Inst.* 86: 872-873, 1994.
6. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T., and Kallioniemi, O.-P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer, *Cancer Res.* 57: 314-319, 1997.
7. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer, *Nat. Genet.* 9: 401-406, 1995.
8. McPhaul, M. J., Marcelli, M., Tilley, W. D., Griffin, J. E., and Wilson, J. D. Androgen resistance caused by mutations in the androgen receptor gene, *FASEB J.* 5: 2910-2915, 1991.
9. Tsai, M. J., , and O'Malley, B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members, *Annu. Rev. Biochem.* 63: 451-486, 1994.
10. Anzick, S., Kononen, J., Walker, R., Azorsa, D., Tanner, M., Guan, X., Sauter, G., Kallioniemi, O., Trent, J., and Meltzer, P. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer, *Science*. 277: 965-968, 1997.
11. Pratt, W. B. and Welsh, M. J. Chaperone functions of the heat shock proteins associated with steroid receptors, *J. Cell. Biol.* 5: 83-93, 1994.
12. Shibata, H., Spencer, T. E., Onate, S. A., Jenster, G., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action, *Recent Prog. Horm. Res.* 52: 141-164, 1997.
13. Froesch, B. A., Takayama, S., and Reed, J. C. BAG-1L protein enhances androgen receptor function, *J. Biol. Chem.* 273: 11660-11666, 1998.